EN
Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
Pfizer Reshapes Portfolio With Metsera Deal Novavax Pact And R&D Push - Simply Wall St News
Novavax (NASDAQ:NVAX) Downgraded to "Sell" Rating by Wall Street Zen - Markets Daily
Pfizer Reshapes Portfolio With New Partnerships Oncology Push And Pricing Shifts
Novavax, Inc. (NASDAQ:NVAX) Given Average Rating of "Hold" by Analysts
Assessing Novavax (NVAX) Valuation After Pfizer Licensing Deal For Matrix M Adjuvant
Novavax (NASDAQ:NVAX) Stock Rating Upgraded by Wall Street Zen - Daily Political
Strs Ohio Buys 134,516 Shares of Pfizer Inc. $PFE - Markets Daily
Will Licensing Novavax's Matrix-M Adjuvant Reshape Pfizer's (PFE) Vaccine Platform Strategy?
Reassessing Novavax (NVAX) After Recent Share Price Rebound And Valuation Signals
Pfizer Inc. $PFE Position Raised by Strs Ohio - Stock Observer
The Bull Case For Pfizer (PFE) Could Change Following Novavax Matrix-M Adjuvant Licensing Deal - Learn Why
Why Are Novavax (NVAX) Shares Soaring Today
Traders Buy Large Volume of Call Options on Novavax (NASDAQ:NVAX)
Stock Traders Buy High Volume of Novavax Call Options (NASDAQ:NVAX) - Daily Political
Novavax signs licensing agreement with Pfizer for vaccine development
Assessing Novavax (NVAX) Valuation After Pfizer Matrix M Licensing Deal
Novavax (NASDAQ:NVAX) Stock Price Up 8% - Still a Buy?
Novavax's (NVAX) Buy Rating Reiterated at BTIG Research
Pfizer is paying $30 million to…
Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln
Is Novavax's (NVAX) Partner-Led Shift With Sanofi Quietly Rewriting Its Risk-Reward Equation? - Simply Wall St News
Novavax (NASDAQ:NVAX) Trading 5.5% Higher - Here's Why - Markets Daily
Novavax (NASDAQ:NVAX) Trading Down 6.1% - What's Next?
Novavax (NASDAQ:NVAX) Trading Down 6.1% - Should You Sell? - Daily Political
Novavax (NASDAQ:NVAX) Trading 5.5% Higher - Here's What Happened
Novavax (NASDAQ:NVAX) Stock Price Up 5.5% - Still a Buy? - Stock Observer
Why Novavax (NVAX) Is Up 9.2% After Singapore Backs Nuvaxovid And Analysts Hike Estimates
